Biota holdings ltd
WebNov 13, 2012 · Results of Biota shareholder meeting. 23 Oct 2012 3:42PM. $0.630. $0.570. $0.570. fallen by 9.52%. + Company announcements and prices are delayed by at least … WebBiota Holdings Limited's current share price is $0.57. This constitutes a share price movement of 0% when compared to its closing share price of $0.57 seven days ago. Relative to today's opening stock price, the BTA stock …
Biota holdings ltd
Did you know?
WebBiota Holdings Limited is engaged in the drug discovery and clinical development of anti-infectives, suitable for human use and commercialization. The Company licensed zanamivir, which is a neuraminidase inhibitor (influenza antiviral), to GlaxoSmithKline (GSK) and marketed as Relenza. The Company’s research breakthroughs include a series of ... WebBiota Holdings. Manufacturing · 52 Employees . Biota Holdings Ltd is a company that operates in the Pharmaceuticals industry. It employs 51-100 people and has $10M-$25M …
WebAug 17, 2011 · Biota Holdings Limited (ASX: BTA) today announced a net loss after tax of $28.1 million (F10: $16.2m profit). Loss before tax was $29.2 million (F10: $20.3m profit). Total revenues were $17.1 million compared to $71.5 million in F2010 when the Company benefited from significant royalties from Relenza due to the H1N1 pandemic. WebBiota Holdings Limited is an Australian company engaged in anti-infective drug discovery and development, and its commercialization, with key …
WebOct 30, 2012 · Biota Holdings Ltd. (ASX:BTA) entered into a merger implementation agreement to acquire Nabi Biopharmaceuticals (NasdaqGS:NABI) from Xstelos … WebWHEREAS, the Company intends to into a Merger Implementation Agreement, by and between Biota Holdings Limited (“Biota”) and the Company (the “Merger Agreement”) pursuant to which the Company will acquire all of Biota’s issued shares pursuant to a scheme of arrangement in consideration for the Company issuing Common Stock to …
WebFind company research, competitor information, contact details & financial data for BIOTA HOLDINGS PTY LTD of Melbourne, VICTORIA. Get the latest business insights from …
WebBiota Holdings Limited engages in the drug discovery and clinical development of anti-infectives in Australia. Licensed & Marketed Products Relenza: Zanamivir (Relenza) was licensed to GlaxoSmithKline... flying colors aerial yogaWebMay 14, 2012 · MELBOURNE, AUSTRALIA--(Marketwire - May 11, 2012) - Biota Holdings Limited (ASX: BTA) today announced that Daiichi Sankyo Co., Ltd. have provided written confirmation that Inavir® gross sales were JPY8.7bn and indicative royalties were $3.4 million for the three months ended 31 March 2012. Royalties for the nine months to 31 … flying colony pods smacWebNov 22, 2024 · BIOTA HOLDINGS PTE. LTD. (the "Company") is a Exempt Private Company Limited by Shares, incorporated in Singapore . The address of the Company's registered office is at the M-SPACE building. The Company current operating status is live. This Company's principal activity is other holding companies. Corporate Profile of … flying collectionWebAug 9, 2007 · Biota Holdings Limited today announced a full year profit after tax of US$17.2 million after initial booking of deferred tax assets. This compares to a loss of … greenlight insurance bmwWebApr 23, 2012 · ROCKVILLE, Md., April 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced plans to merge with Biota … flying colors auto body shopWebAdd photo Location & Hours 585 Blackburn Rd #10 Notting Hill Victoria 3168 Australia Get directions Edit business info Recommended Reviews Your trust is our top concern,so businesses can't pay to alter or remove their reviews. Learn more. Username Location 0 0 1 star rating Not good 2 star rating Could’ve been better 3 star rating OK 4 star rating greenlight insurance njWebMay 16, 2012 · Biota Holdings Limited Biota is a leading anti-infective drug development company based in MelbourneAustralia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. greenlight insurance agency